Fei Su
Impact in
-
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
-
- Advanced Breast Cancer Therapies
Papers in
- Oncology 9
- HER2/EGFR in Cancer Research 3
- Lung Cancer Research Studies 2
- PARP inhibition in cancer therapy 2
-
- Advanced Breast Cancer Therapies 8
- Co-authors
- Nadia Solovieff (4 shared papers)Naveen Babbar (3 shared papers)Tetiana Taran (2 shared papers)Agnes Lteif (2 shared papers)Nuria Chic (1 shared paper)Laia Paré (1 shared paper)Anwesha Chaudhury (1 shared paper)Olga Martínez-Sáez (1 shared paper)
- Journals
- Annals of Oncology (4 papers)Journal of Clinical Oncology (2 papers)Dose-Response (2 papers)Journal of Neuroendocrinology (1 paper)Cancer Science (1 paper)
- Partner nations
- ChinaUnited StatesSpain
In The Last Decade
Fei Su
24 papers receiving 382 citations
Peers
Comparison fields: 5 of 57
- Cancer Research 106
- Pulmonary and Respiratory Medicine 204
- Oncology 142
- Genetics 36
- Public Health, Environmental and Occupational Health 42
Countries citing papers authored by Fei Su
This map shows the geographic impact of Fei Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fei Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fei Su more than expected).
Fields of papers citing papers by Fei Su
This network shows the impact of papers produced by Fei Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fei Su. The network helps show where Fei Su may publish in the future.
Co-authors
The 25 scholars most cited alongside Fei Su, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 30 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 117 | |
| 2 | 2019 | 45 | |
| 3 | 2021 | 35 | |
| 4 | 2023 | 30 | |
| 5 | 2023 | 20 | |
| 6 | 2018 | 18 | |
| 7 | 2023 | 18 | |
| 8 | 2012 | 17 | |
| 9 | 2020 | 15 | |
| 10 | 2016 | 11 | |
| 11 | 2020 | 11 | |
| 12 | 2019 | 10 | |
| 13 | 2019 | 8 | |
| 14 | 2021 | 7 | |
| 15 | 2023 | 7 | |
| 16 | 2023 | 5 | |
| 17 | 2017 | 3 | |
| 18 | 2022 | 3 | |
| 19 | 2022 | 2 | |
| 20 | 2025 | 2 |
About Fei Su
Fei Su is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Hematology, Public Health, Environmental and Occupational Health and Radiology, Nuclear Medicine and Imaging, having authored 30 papers that have together received 390 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (8 papers), Mosquito-borne diseases and control (4 papers), Viral Infections and Vectors (3 papers), HER2/EGFR in Cancer Research (3 papers), Cancer Genomics and Diagnostics (2 papers), Malaria Research and Control (2 papers), Lung Cancer Research Studies (2 papers) and PARP inhibition in cancer therapy (2 papers). The work is most often cited by research in Cancer Research (106 citations), Pulmonary and Respiratory Medicine (204 citations), Oncology (142 citations), Genetics (36 citations) and Public Health, Environmental and Occupational Health (42 citations). Fei Su has collaborated with scholars based in China, United States and Spain. Frequent co-authors include Nadia Solovieff, Naveen Babbar, Tetiana Taran, Agnes Lteif, Nuria Chic, Laia Paré, Anwesha Chaudhury, Olga Martínez-Sáez, Fara Brasó Maristany and Yoon Sim Yap. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Dose-Response, Journal of Neuroendocrinology and Cancer Science.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.